SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
